STOCKHOLM, Jan. 27, 2021 /PRNewswire/ -- Alligator
Bioscience AB (publ) ("Alligator" or the "Company") has completed
the share issue with pre-emption rights for the Company's
shareholders, which was resolved upon by the Board of Directors on
December 15, 2020 pursuant to the
authorization from the annual general meeting on May 5, 2020 (the "Rights Issue"). The
subscription period ran from and including January 11, 2021 to and including January 25, 2021. Through the Rights Issue,
Alligator receives approximately SEK 86
million before deduction of issue costs. 13 895 925
shares, corresponding to approximately 97 per cent of the Rights
Issue, were subscribed for by exercise of subscription rights
(including subscription undertakings). Furthermore, 9 305 467
shares were subscribed for without subscription rights,
corresponding to approximately 65 per cent of the Rights Issue. In
total, the Rights Issue was subscribed for at 163 per cent.
Guarantee commitments made in connection with the Rights Issue will
thus not be utilized.
Alligator has carried out the Rights Issue to initiate and
conduct Phase II studies for mitazalimab and to complete Phase I
study and initiate preparatory work on Phase II study for
ATOR-1017.
Comment from Alligator's CEO, Per
Norlén
"I would like to extend my warm gratitude to existing and new
shareholders for their strong support. The capital injection
secures the start of the important efficacy study with mitazalimab
in pancreatic cancer. In parallel planning is ongoing for a similar
efficacy study with ATOR-1017 in gastric cancer
patients." - Per Norlén, CEO.
Outcome
The Rights Issue comprised a maximum of 14,277,723 shares, of which
13 895 925 shares, corresponding to approximately 97 per cent
of the Rights issue, has been subscribed for by exercise of
subscription rights. A total of 9 305 467 shares,
corresponding to approximately 65 per cent of the Rights Issue, has
been subscribed for without use of subscription rights. Thus,
23 201 392 shares, corresponding to approximately 163 per cent
of the Rights Issue, has been subscribed for with and without use
of subscription rights. Guarantee commitments made in connection
with the Rights Issue will thus not be utilized. Through the Rights
Issue, Alligator receives approximately SEK
86 million before deduction of issue costs, which are
estimated to approximately SEK 10
million.
Notification regarding allocation
Allocation of shares has been made in accordance with the
allocation principles described in the prospectus that was
published by the Company in connection with the Rights Issue (the
"Prospectus"). A notification regarding allocation of shares
subscribed for without subscription rights will be made by post of
a contract note to each subscriber. Allocated shares subscribed for
without subscription rights shall be paid for in accordance with
the instructions in the contract note.
Trading in BTA
Trading in BTA (Sw. betald tecknad aktie) is currently
taking place at Nasdaq Stockholm and will cease when the Rights
Issue has been registered by the Swedish Companies Registration
Office, which is expected to take place around week 7, 2021. BTA:s
will then be converted to ordinary shares.
Number of shares and share capital
Through the Rights Issue, the number of shares in the Company
increases by 14,277,723 shares, from 71,388,615 shares to
85,666,338 shares. The company's share capital increases by
SEK 5,711,089.20, from SEK 28,555,446 to SEK
34,266,535.20. The Rights Issue entails a dilution of
approximately 16.67 per cent for shareholders who are not
participating in the Rights Issue.
Advisers
Redeye AB acts as financial adviser, Setterwalls Advokatbyrå AB
acts as legal adviser and Aktieinvest FK AB acts as issuing agent
in connection with the Rights Issue.
For more information, please contact:
Per Norlén, CEO
Phone: +46 46 540 82 00
E-mail: per.norlen@alligatorbioscience.com
Cecilia Hofvander, Director
Investor Relations & Communications
Phone: +46 46-540 82 06
E-mail: cecilia.hofvander@alligatorbioscience.com
This information is information that Alligator Bioscience AB
is obliged to make public pursuant to the EU Market Abuse
Regulation. The information was submitted for publication, through
the agency of the contact persons set out above, at 6.20 p.m. CET on January
27, 2021.
About Alligator Bioscience AB
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
Alligator's pipeline includes the two key assets ATOR-1017 and
mitazalimab. Furthermore, there are two partnered assets:
ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and
AC101 in clinical development by Shanghai Henlius Biotech Inc. In
addition, the company has developed a novel concept for more
patient-specific immunotherapy: Neo-X-Prime. Alligator's shares are
listed on Nasdaq Stockholm (ATORX). The Company is headquartered in
Lund, Sweden. For more
information, please visit http://www.alligatorbioscience.com.
IMPORTANT INFORMATION
The information in this press release does not contain or
constitute an offer to acquire, subscribe or otherwise trade in
shares or other securities in Alligator. No action has been taken
and measures will not be taken to permit a public offering in any
jurisdictions other than Sweden.
Any invitation to the persons concerned to subscribe for shares in
Alligator has only been made through the Prospectus that was
published by the Company on December 30,
2020. The Prospectus has been approved and registered by the
Swedish Financial Supervisory Authority and has been published on
http://www.alligatorbioscience.com. The approval of the Prospectus
by the Swedish Financial Supervisory Authority shall not be
regarded as an approval of the shares or any other securities. This
release is however not a prospectus in accordance to the definition
in the Prospectus Regulation (EU) 2017/1129 ("Prospectus
Regulation") and this announcement does not identify or
suggest, or purport to identify or suggest, the risks (direct or
indirect) that may be associated with an investment in shares or
other securities in Alligator. In order for investors to
fully understand the potential risks and benefits associated with a
decision to participate in the Rights Issue, any investment
decision should only be made based on the information in the
Prospectus. Thus, investors are encouraged to review the Prospectus
in its entirety.
The information in this press release may not be released,
distributed or published, directly or indirectly, in or into
the United States of America,
Canada, New Zealand, South
Africa, Japan, Australia, South
Korea, Hong Kong,
Switzerland, Singapore or any other jurisdiction in which
such action would be unlawful or would require registration or any
other measures than those required by Swedish law. Actions in
violation of these restrictions may constitute a violation of
applicable securities laws. No shares or other securities in
Alligator have been registered, and no shares or other securities
will be registered, under the United States Securities Act of 1933,
as amended (the "Securities Act") or the securities
legislation of any state or other jurisdiction in the United States and no shares or other
securities may be offered, sold or otherwise transferred, directly
or indirectly, in or into the United
States, except under an available exemption from, or in a
transaction not subject to, the registration requirements under the
Securities Act and in compliance with the securities legislation in
the relevant state or any other jurisdiction of the United States.
Within the European Economic Area ("EEA"), no public
offering of Securities is made in other countries than Sweden. In other member states of the EU, such
an offering of Securities may only be made in accordance with the
Prospectus Regulation (EU) 2017/1129. In other member states of the
EEA which have implemented the Prospectus Regulation in its
national legislation, any offer of Securities may only be made in
accordance with an applicable exemption in the Prospectus
Regulation and/or in accordance with an applicable exemption under
a relevant national implementation measure. In other member states
of the EEA which have not implemented the Prospectus Regulation in
its national legislation, any offer of Securities may only be made
in accordance with an applicable exemption under national law.
This communication is only being distributed to and is only
directed at persons in the United
Kingdom that are (i) investment professionals falling within
Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005, as amended (the "Order")
or (ii) high net worth entities, and other persons to whom this
announcement may lawfully be communicated, falling within Article
49(2)(a) to (d) of the Order (all such persons together being
referred to as "Relevant Persons"). This communication must
not be acted on or relied on by persons who are not Relevant
Persons. Any investment or investment activity to which this
communication relates is available only to Relevant Persons and
will be engaged in only with Relevant Persons. Persons distributing
this communication must satisfy themselves that it is lawful to do
so.
This press release may contain forward-looking statements which
reflect the Company's current view on future events and financial
and operational development. Words such as "intend", "expect",
"anticipate", "may", "believe", "plan", "estimate" and other
expressions which imply indications or predictions of future
development or trends, and which are not based on historical facts,
are intended to identify forward-looking statements.
Forward-looking statements inherently involve both known and
unknown risks and uncertainties as they depend on future events and
circumstances. Forward-looking statements do not guarantee future
results or development and the actual outcome could differ
materially from the forward-looking statements.
The English text is an unofficial translation of the original
Swedish text. In case of any discrepancies between the Swedish text
and the English translation, the Swedish text shall prevail.
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR
INDIRECTLY, IN OR INTO, THE UNITED STATES
OF AMERICA, CANADA,
NEW ZEALAND, SOUTH AFRICA, JAPAN, AUSTRALIA, SOUTH
KOREA, HONG KONG,
SWITZERLAND, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH
THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR
REQUIRE REGISTRATION OR ANY OTHER MEASURE.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-s-rights-issue-oversubscribed,c3275162
The following files are available for download:
https://mb.cision.com/Main/12681/3275162/1364438.pdf
|
Alligator
Bioscience’s rights issue oversubscribed
|